Response evaluation in patients with colorectal liver metastases: RECIST version 1.1 versus modified CT criteria

American Journal of Roentgenology

Volumn 199, Issue 4, 2012, Pages 809-815

  Chung, Woo Suk ^a   Park, Mi Suk ^a   Shin, Sang Joon ^a   Baek, Song Ee ^a   Kim, Yeo Eun ^a   Choi, Jin Young ^a   Kim, Myeong Jin ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Colorectal cancer; Liver metastasis; Modified CT criteria; RECIST 1.1; Response Evaluation Criteria in Solid Tumors (RECIST); Treatment response; Tumor density; Tumor size

Indexed keywords

BEVACIZUMAB; FLUOROURACIL; FOLINIC ACID; IOPROMIDE; IRINOTECAN; OXALIPLATIN;

ADULT; AGED; ARTICLE; ATTENUATION; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PROGNOSIS; COLORECTAL CARCINOMA; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT RESPONSE; TUMOR VOLUME;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; CONTRAST MEDIA; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IOHEXOL; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTIDETECTOR COMPUTED TOMOGRAPHY; PROGNOSIS;

EID: 84866859311     PISSN: 0361803X     EISSN: 15463141     Source Type: Journal    
DOI: 10.2214/AJR.11.7910     Document Type: Article

References (20)

1. Rubbia-Brandt L, Giostra E, Brezault C, et al. Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery. Ann Oncol 2007; 18:299-304 (Pubitemid 46323097)
2. Adam R, Pascal G, Castaing D, et al. Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases? Ann Surg 2004; 240:1052-1061; discussion, 1061-1064
3. Adam R, Wicherts DA, de Haas RJ, et al. Complete pathologic response after preoperative chemotherapy for colorectal liver metastases: myth or reality? J Clin Oncol 2008; 26:1635-1641
4. Blazer DG 3rd, Kishi Y, Maru DM, et al. Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol 2008; 26: 5344-5351
5. Grothey A, Hedrick EE, Mass RD, et al. Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107. J Clin Oncol 2008; 26:183-189
6. Choi H, Charnsangavej C, Faria SC, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 2007; 25:1753-1759 (Pubitemid 46797957)
7. Chun YS, Vauthey JN, Boonsirikamchai P, et al. Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases. JAMA 2009; 302:2338-2344
8. Eisenhauer EA, Therasse P, Bogaerts J, et al. New Response Evaluation Criteria in Solid Tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45:228-247
9. van Persijn van Meerten EL, Gelderblom H, Bloem JL. RECIST revised: implications for the radiologist- a review article on the modified RECIST guideline. Eur Radiol 2010; 20:1456-1467
10. Klinger M, Tamandl D, Eipeldauer S, et al. Bevacizumab improves pathological response of colorectal cancer liver metastases treated with XELOX/FOLFOX. Ann Surg Oncol 2010; 17:2059-2065
11. Ribero D, Wang H, Donadon M, et al. Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases. Cancer 2007; 110:2761-2767 (Pubitemid 350250347)
12. Javle M, Hsueh CT. Recent advances in gastrointestinal oncology: updates and insights from the 2009 annual meeting of the American Society of Clinical Oncology. J Hematol Oncol 2010; 3:11
13. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the Response to Treatment in Solid Tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205-216
14. Kan Z, Phongkitkarun S, Kobayashi S, et al. Functional CT for quantifying tumor perfusion in antiangiogenic therapy in a rat model. Radiology 2005; 237:151-158 (Pubitemid 41346159)
15. Park MS, Klotz E, Kim MJ, et al. Perfusion CT: noninvasive surrogate marker for stratification of pancreatic cancer response to concurrent chemo- and radiation therapy. Radiology 2009; 250:110-117
16. Provenzale JM. Imaging of angiogenesis: clinical techniques and novel imaging methods. AJR 2007; 188:11-23 (Pubitemid 46012485)
17. Sabir A, Schor-Bardach R, Wilcox CJ, et al. Perfusion MDCT enables early detection of therapeutic response to antiangiogenic therapy. AJR 2008; 191:133-139 (Pubitemid 351955217)
18. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010; 30:52-60
19. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 2001; 7:987-989 (Pubitemid 32937367)
20. Tong RT, Boucher Y, Kozin SV, et al. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 2004; 64:3731-3736 (Pubitemid 38697278)